Epigenetic Therapy in Human Choriocarcinoma
Abstract
:1. Introduction
Substance groups | Derivatives | Isotype |
---|---|---|
Hydroxamates | Trichostatin A (TSA) | I, II |
Suberoylanilide hydroxamic acid (SAHA, vorinostat) | I, II, IV | |
LBH589 (panobinostat) | I, II, IV | |
PCI24781 (CRA-024781) | I, IIb | |
LAQ824 | I, II | |
PXD101 (belinostat) | I, II, IV | |
ITF2357 | I, II | |
SB939 | Unknown | |
JNJ-16241199 (R306465) | I | |
m-carboxycinnamic acid bishydroxamide (CBHA) | ||
Scriptaid | ||
Oxamflatin | ||
Pyroxamide | ||
Cyclic hydroxamic acid containing peptides (CHAPs) | ||
Short chain fatty acids | Butyrate | I, IIa |
Valproate | I, Iia | |
AN-9 | ||
OSU-HDAC42 | ||
Benzamides | MS-275 (entinostat) | 1, 2, 3, 9 |
MGCD0103 | 1, 2, 3, 11 | |
Pimelic diphenylamide | 1, 2, 3 | |
M344 | ||
Cyclic tetrapeptides | Apicidine | I, II |
Trapoxins | ||
HC-toxin | ||
Chlamydocin | ||
Depsipeptide (FR901228 or FK228) (romidepsin) | 1, 2, 4, 6 | |
Sulfonamide anilides | N-2-aminophenyl-3-[4-(4-methylbenzenesulfonylamino)-phenyl]-2-propenamide | |
Others | Depudecin | |
NDH-51 | ||
KD5150 | Pan-HDACI |
2. Mechanism of Action
3. Preclinical Epigenetic Therapy in Choriocarcinoma
4. Conclusions and Future Directions
5. Conflict of Interest
Acknowledgments
References
- Jones, W.B.; Cardinale, C.; Lewis, J.L., Jr. Management of the high-risk gestational trophoblastic disease: the Memorial Hospital experience. Int. J. Gynecol. Cancer 1997, 7, 27–33. [Google Scholar]
- Berkowitz, R.S.; Goldstein, D.P.; Bernstein, M.R. Modified triple chemotherapy in the management of high-risk gestational trophoblastic tumors. Gynecol. Oncol. 1984, 19, 173–181. [Google Scholar] [CrossRef]
- Surwit, E.A.; Hammond, C.B. Treatment of metastatic trophoblastic disease with poor prognosis. Obstet. Gynecol. 1980, 55, 565–570. [Google Scholar]
- Strahl, B.D.; Allis, C.D. The language of covalent histone modifications. Nature 2000, 403, 41–45. [Google Scholar] [CrossRef]
- Jenuwein, T.; Allis, C.D. Translating the histone code. Science 2001, 293, 1074–1080. [Google Scholar] [CrossRef]
- Bolden, J.E.; Peart, M.J.; Johnstone, R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 2006, 5, 769–784. [Google Scholar] [CrossRef]
- Takai, N.; Narahara, H. Human endometrial and ovarian cancer cells: Histone deacetylase inhibitors exhibit antiproliferative activity, potently induce cell cycle arrest, and stimulate apoptosis. Curr. Med. Chem. 2007, 14, 2548–2553. [Google Scholar] [CrossRef]
- Tan, J.; Cang, S.; Ma, Y.; Petrillo, R.L.; Liu, D. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J. Hematol. Oncol. 2010, 3, 5. [Google Scholar] [CrossRef]
- Cang, S.; Ma, Y.; Liu, D. New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. J. Hematol. Oncol. 2009, 2, 22. [Google Scholar] [CrossRef]
- Siegel, D.; Hussein, M.; Belani, C.; Robert, F.; Galanis, E.; Richon, V.M.; Garcia-Vargas, J.; Sanz-Rodriguez, C.; Rizvi, S. Vorinostat in solid and hematologic malignancies. J. Hematol. Oncol. 2009, 2, 31. [Google Scholar] [CrossRef]
- Haberland, M; Montgomery, R.L.; Olson, E.N. The many roles of histone deacetylases in development and physiology: Implications for disease and therapy. Nat. Rev. Genet. 2009, 10, 32–42. [Google Scholar] [CrossRef]
- Kakai, N; Kawamata, N.; Gui, D.; Said, J.W.; Miyakawa, I.; Koeffler, H.P. Human ovarian carcinoma cells: histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer 2004, 101, 2760–2770. [Google Scholar] [CrossRef]
- Gui, C.Y.; Ngo, L.; Xu, W.S.; Richon, V.M.; Marks, P.A. Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. Proc. Natl. Acad. Sci. USA 2004, 101, 1241–1246. [Google Scholar] [CrossRef]
- Takai, N.; Ueda, T.; Nishida, M.; Nasu, K.; Narahara, H. Histone deacetylase inhibitors induce growth inhibition, cell cycle arrest and apoptosis in human choriocarcinoma cells. Int. J. Mol. Med. 2008, 21, 109–115. [Google Scholar]
- Ruefli, A.A.; Ausserlechner, M.J.; Bernhard, D.; Sutton, V.R.; Tainton, K.M.; Kofler, R.; Smyth, M.J.; Johnstone, R.W. The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc. Natl. Acad. Sci. USA 2001, 98, 10833–10838. [Google Scholar] [CrossRef]
- Xu, W.; Ngo, L.; Perez, G.; Dokmanovic, M.; Marks, P.A. Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc. Natl. Acad. Sci. USA 2006, 103, 15540–15545. [Google Scholar] [CrossRef]
- Rosato, R.R.; Almenara, J.A.; Grant, S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1. Cancer Res. 2003, 63, 3637–3645. [Google Scholar]
- Marchion, D.; Mnster, P. Development of histone deacetylase inhibitors for cancer treatment. Expert Rev. Anticancer Ther. 2007, 7, 583–598. [Google Scholar] [CrossRef]
- Gregorie, C.J.; Wiesen, J.L.; Magner, W.J.; Lin, A.W.; Tomasi, T.B. Restoration of immune response gene induction in trophoblast tumor cells associated with cellular senescence. J. Reprod. Immunol. 2009, 81, 25–33. [Google Scholar] [CrossRef]
- Rahnama, F.; Shafiei, F.; Gluckman, P.D.; Mitchell, M.D.; Lobie, P.E. Epigenetic regulation of human trophoblastic cell migration and invasion. Endocrinology 2006, 147, 5275–5283. [Google Scholar] [CrossRef]
© 2010 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
Share and Cite
Takai, N.; Narahara, H. Epigenetic Therapy in Human Choriocarcinoma. Cancers 2010, 2, 1683-1688. https://doi.org/10.3390/cancers2031683
Takai N, Narahara H. Epigenetic Therapy in Human Choriocarcinoma. Cancers. 2010; 2(3):1683-1688. https://doi.org/10.3390/cancers2031683
Chicago/Turabian StyleTakai, Noriyuki, and Hisashi Narahara. 2010. "Epigenetic Therapy in Human Choriocarcinoma" Cancers 2, no. 3: 1683-1688. https://doi.org/10.3390/cancers2031683
APA StyleTakai, N., & Narahara, H. (2010). Epigenetic Therapy in Human Choriocarcinoma. Cancers, 2(3), 1683-1688. https://doi.org/10.3390/cancers2031683